{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000231","form_type":"8-K","ticker":null,"cik":"0001300734","company_name":"SHINECO, INC.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.314917+00:00","generated_at":"2026-06-20T20:12:02.468820+00:00","sec_items":["2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Shineco completes acquisition of 51% of Changzhou Biowin Pharmaceutical for $9M cash + 3.26M shares","bullets":["Total consideration ~$12.1M: $9M cash plus 3.26M SISI shares valued at $0.95/share (~$3.1M).","Acquisition closed Dec 30, 2022; subsidiary Shineco Life Science Research acquired 51% stake from Beijing Kanghuayuan.","Performance targets for 2023-2025: 2023 rev >=RMB35M, net profit >=RMB5.5M; 2024 rev >=RMB50M, net profit >=RMB10M; 2025 rev >=RMB80M, net profit >=RMB20M.","Financial statements of Biowin to be filed by amendment within 71 days of 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000231","json":"https://secwatch.observer/filing/0001493152-23-000231.json","markdown":"https://secwatch.observer/filing/0001493152-23-000231.md","text":"https://secwatch.observer/filing/0001493152-23-000231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/0001493152-23-000231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:12:02.468820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd131eb443505650e30d41b190da01966b93448c","claim":"SHINECO, INC. completed an acquisition involving Beijing Kanghuayuan Medicine Information Consulting Co., Ltd. for US $9 million in cash and the Company issued 3,260,000 shares of the Company’s common stock (closed 2022-12-30).","evidence_excerpt":"established under the laws of China (“Seller”) Biowin, the Company and Subsidiary (the “Agreement”). As the consideration for the acquisition, the Company paid to Seller US $9 million in cash and the Company issued 3,260,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) to the equity holders of Biowen or","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/0001493152-23-000231-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Beijing Kanghuayuan Medicine Information Consulting Co., Ltd."},{"label":"Consideration","value":"US $9 million in cash and the Company issued 3,260,000 shares of the Company’s common stock"},{"label":"Closing","value":"2022-12-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}